Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetesTeruo Jojima, Yoshimasa Aso|Diabetology & Metabolic Syndrome|2016Cited by 199